Business Wire: May 24, 2017 – PARIS, France, and CAMBRIDGE, MA, U.S.A. – Lysogene (Paris: LYS) (FR0013233475 – LYS), a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system diseases, today announced that it has entered into a strategic manufacturing…
